The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptor

Project Details

Description

Project Narrative (Public Health Relevance):
Chronic pain, drug addiction, anxiety and depression each extract substantial health and socioeconomic costs
from the American populace. Although drugs directed toward the kappa opioid receptor (KOR) have been
investigated as treatments for these human ailments, they are currently hampered by poor side effect profiles.
A deeper understanding of the mechanisms by which the proteins RGS12 and β-arrestin2 regulate the beneficial
versus detrimental effects of KOR-directed drugs will enable new strategies to maximize the clinical utility of
these (and future) drugs that provide pain relief by targeting opioid receptors, but without addiction or side effect
liabilities.
StatusActive
Effective start/end date15/02/2131/12/22

Funding

  • National Institute on Drug Abuse: $323,812.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.